The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Evaluating pCR as a surrogate endpoint for OS in esophageal cancer
Jun Okui, MD, MPH, Keio University School of Medicine, Tokyo, Japan, presents findings from an international collaborative study investigating whether pathological complete response (pCR) can serve as a surrogate endpoint for overall survival (OS) in esophageal cancer. The study analyzed a large patient population across several countries who underwent neoadjuvant chemotherapy or chemoradiotherapy followed by surgery. Results showed a weak correlation between pCR and OS, suggesting that while pCR can stratify prognosis, it may not reliably substitute for OS as a primary endpoint in clinical trials. These findings provide valuable insights for optimizing future trial designs and treatment benefit predictions. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
